Research progress of active components of Astragalus membranaceus in improving lipid metabolism disorder of diabetic kidney disease

doi:10.12092/j.issn.1009-2501.2026.07.009

Abstract

Abstract:

Diabetic kidney disease (DKD) is a common microvascular complication secondary to diabetes. Its incidence is increasing year by year, which seriously threatens the prognosis and quality of life of diabetic patients. At present, the clinical treatment options for DKD are limited, and it is difficult to effectively prevent its progression. In the complex pathophysiological mechanism of DKD, lipid metabolism disorder plays an important role, which not only promotes lipid deposition in the kidney, but also accelerates the process of renal injury through lipid toxicity. In recent years, Chinese herbal medicine has attracted much attention because of its significant effect in improving DKD lipid metabolism disorder. Astragalus membranaceus is a commonly used Chinese herbal medicine for the treatment of DKD, which shows significant renal protective effect in the treatment of DKD. Astragalus membranaceus is rich in Astragaloside Ⅳ, formononetin, quercetin, kaempferol and other active ingredients. It shows unique advantages in improving DKD lipid metabolism disorders. It can not only effectively improve lipid metabolism disorders, but also reduce renal lipid deposition. This article systematically reviews the research progress of the effect of Astragalus active ingredients on improving lipid metabolism disorders in DKD, and provides a theoretical basis for clinical treatment of DKD strategies.

Key words: diabetic kidney disease, Astragalus membranaceus, active ingredients, lipid homeostasis, Chinese herbal medicine

CLC Number:

Liping ZHENG, Han ZHU, Keqin ZHAO, Yong HUANG, Peng LIU. Research progress of active components of Astragalus membranaceus in improving lipid metabolism disorder of diabetic kidney disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(7): 928-936.

Figures/Tables 2

References 63

1	Liu D, Chen X, He W, et al. Update on the pathogenesis, diagnosis, and treatment of diabetic tubulopathy[J]. Integr Med Nephrol Androl, 2024, 11 (4): e23.
2	Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183, 109119. doi: 10.1016/j.diabres.2021.109119
3	Uma A, Sivaraman S, Manoharan R, et al. Diabetic kidney disease in type 2 diabetes: a comprehensive review of epidemiology, pathophysiology, and therapeutic advances[J]. J Pharm Bioallied Sci, 2025, 17 (2): 33- 35. doi: 10.4103/jpbs.jpbs_1059_25
4	Zhao H, Li Z, Yan M, et al. Irbesartan ameliorates diabetic kidney injury in db/db mice by restoring circadian rhythm and cell cycle[J]. J Transl Intern Med, 2024, 12 (2): 157- 169. doi: 10.2478/jtim-2022-0049
5	Wang X, Liu J, Liu T, et al. Discovery of the pharmacodynamic material basis of Danggui Buxue Decoction in the treatment of diabetic kidney disease based on lipidomics regulation[J]. Phytomedicine, 2025, 141, 156643. doi: 10.1016/j.phymed.2025.156643
6	Deng Y, Zhu H, Xing J, et al. The role of natural products in improving lipid metabolism disorder-induced mitochondrial dysfunction of diabetic kidney disease[J]. Front Physiol, 2025, 16, 1624077. doi: 10.3389/fphys.2025.1624077
7	Zhao H, Zhao T, Li P. Gut microbiota-derived metabolites: a new perspective of traditional chinese medicine against diabetic kidney disease[J]. Integr Med Nephrol Androl, 2024, 11 (2): e23. doi: 10.1097/imna-d-23-00024
8	Guo MF, Dai YJ, Gao JR, et al. Uncovering the mechanism of astragalus membranaceus in the treatment of diabetic nephropathy based on network pharmacology[J]. J Diabetes Res, 2020, 2020, 1- 13. doi: 10.21203/rs.3.rs-48440/v1
9	Zhu Z, Zhang Q, Liu L, et al. Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: protocol for a systematic review and meta-analysis[J]. Medicine (Baltimore), 2022, 101 (49): e31490.
10	Liu J, Yang K, Zhou L, et al. A new strategy for Astragaloside Ⅳ in the treatment of diabetic kidney disease: analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells[J]. Int Immunopharmacol, 2024, 141, 112794. doi: 10.1016/j.intimp.2024.112794
11	Chen Q, Su Y, Ju Y, et al. Astragalosides Ⅳ protected the renal tubular epithelial cells from free fatty acids-induced injury by reducing oxidative stress and apoptosis[J]. Biomed Pharmacother, 2018, 108, 679- 686. doi: 10.1016/j.biopha.2018.09.049
12	Wang Y, Liu T, Wu Y, et al. Lipid homeostasis in diabetic kidney disease[J]. Int J Biol Sci, 2024, 20 (10): 3710- 3724.
13	Mitrofanova A, Burke G, Merscher S, et al. New insights into renal lipid dysmetabolism in diabetic kidney disease[J]. World J Diabetes, 2021, 12 (5): 524- 540. doi: 10.4239/wjd.v12.i5.524
14	Huang Y, Xu W, Zhou R. NLRP3 inflammasome activation and cell death[J]. Cell Mol Immunol, 2021, 18 (9): 2114- 2127. doi: 10.1038/s41423-021-00740-6
15	Han JH. Immuno-metabolic diseases and therapeutics: molecular mechanisms via inflammasome signaling[J]. Cell Commun Signal, 2025, 23 (1): 373. doi: 10.1186/s12964-025-02368-9
16	Li X, Dong X, Zhang L, et al. Astragaloside Ⅳ attenuates renal tubule injury in DKD rats via suppression of CD36-mediated NLRP3 inflammasome activation[J]. Front Pharmacol, 2024, 15, 1285797. doi: 10.3389/fphar.2024.1285797
17	Xing L, Guo H, Meng S, et al. Klotho ameliorates diabetic nephropathy by activating Nrf2 signaling pathway in podocytes[J]. Biochem Biophys Res Commun, 2021, 534, 450- 456. doi: 10.1016/j.bbrc.2020.11.061
18	Li Y, Xue M, Hu F, et al. Klotho prevents epithelial-mesenchymal transition through Egr-1 downregulation in diabetic kidney disease[J]. BMJ Open Diab Res Care, 2021, 9 (1): e002038. doi: 10.1136/bmjdrc-2020-002038
19	Yu LX, Sha MY, Chen Y, et al. Potential application of Klotho as a prognostic biomarker for patients with diabetic kidney disease: a Meta-analysis of clinical studies [J]. Ther Adv Chronic Dis, 2023, 14: 20406223231213246.
20	He J, Cui J, Shi Y, et al. Astragaloside Ⅳ attenuates high-glucose-induced impairment in diabetic nephropathy by increasing klotho expression via the NF-κB/NLRP3 axis[J]. J Diabetes Res, 2023, 2023, 1- 22. doi: 10.1155/2023/7423661
21	Liu J, Ren J, Zhou L, et al. Proteomic and lipidomic analysis of the mechanism underlying Astragaloside Ⅳ in mitigating ferroptosis through hypoxia-inducible factor 1α/heme oxygenase 1 pathway in renal tubular epithelial cells in diabetic kidney disease[J]. J Ethnopharmacol, 2024, 334, 118517. doi: 10.1016/j.jep.2024.118517
22	Huang Q, Chen H, Yin K, et al. Formononetin attenuates renal tubular injury and mitochondrial damage in diabetic nephropathy partly via regulating Sirt1/PGC-1α pathway[J]. Front Pharmacol, 2022, 13, 901234. doi: 10.3389/fphar.2022.901234
23	Wu W, Wang X, Yu X, et al. Smad3 signatures in renal inflammation and fibrosis[J]. Int J Biol Sci, 2022, 18 (7): 2795- 2806. doi: 10.7150/ijbs.71595
24	Derynck R, Budi EH. Specificity, versatility, and control of TGF-β family signaling[J]. Sci Signal, 2019, 12 (570): eaav5183. doi: 10.1126/scisignal.aav5183
25	Liu P, Wang C, Wang Y, et al. Zishen Qingre Tongluo Formula improves renal fatty acid oxidation and alleviated fibrosis via the regulation of the TGF-β 1/Smad3 signaling pathway in hyperuricemic nephrology rats[J]. Biomed Res Int, 2021, 2021 (1): 2793823. doi: 10.1155/2021/2793823
26	Dong L, Yu L, Zhong J. Histone lysine-specific demethylase 1 induced renal fibrosis via decreasing sirtuin 3 expression and activating TGF-β1/Smad3 pathway in diabetic nephropathy[J]. Diabetol Metab Syndr, 2022, 14 (1): 2. doi: 10.1186/s13098-021-00771-z
27	Hong Q, Kim H, Cai GY, et al. Modulation of TGF-β signaling new approaches toward kidney disease and fibrosis therapy[J]. Int J Biol Sci, 2025, 21 (4): 1649- 1665. doi: 10.7150/ijbs.101548
28	Ji X, Wang H, Wu Z, et al. Specific inhibitor of Smad3 (SIS3) attenuates fibrosis, apoptosis, and inflammation in unilateral ureteral obstruction kidneys by inhibition of transforming growth factor β (TGF-β)/Smad3 signaling[J]. Med Sci Monit, 2018, 24, 1633- 1641.
29	Lv J, Zhuang K, Jiang X, et al. Renoprotective effect of formononetin by suppressing Smad3 expression in Db/Db mice [J]. Diabetes Metab Syndr Obes, 2020, 13: 3313-3324.
30	Lai W, Wang B, Huang R, et al. Ferroptosis in organ fibrosis: from mechanisms to therapeutic medicines[J]. J Transl Intern Med, 2024, 12 (1): 22- 34. doi: 10.2478/jtim-2023-0137
31	He F, Ru X, Wen T. NRF2, a Transcription factor for stress response and beyond[J]. Int J Mol Sci, 2020, 21 (13): 4777. doi: 10.3390/ijms21134777
32	Neagu M, Constantin C, Surcel M, et al. Diabetic neuropathy: a NRF2 disease ?[J]. J Diabetes, 2024, 16 (9): e13524. doi: 10.1111/1753-0407.13524
33	Chen M, Chen Y, Zhu W, et al. Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress[J]. Biomed Pharmacother, 2023, 165, 115088. doi: 10.1016/j.biopha.2023.115088
34	Chen R, Zeng J, Li C, et al. Fraxin promotes the activation of Nrf2/ARE pathway via increasing the expression of Connexin43 to ameliorate diabetic renal fibrosis[J]. Front Pharmacol, 2022, 13, 853383. doi: 10.3389/fphar.2022.853383
35	Zhuang K, Jiang X, Liu R, et al. Formononetin activates the Nrf2/ARE signaling pathway via Sirt1 to improve diabetic renal fibrosis[J]. Front Pharmacol, 2021, 11, 616378. doi: 10.3389/fphar.2020.616378
36	Yang T, Hu Y, Jiang W, et al. YY1 was indispensable for the alleviation of quercetin on diabetic nephropathy-associated tubulointerstitial inflammation[J]. Phytomedicine, 2023, 111, 154659. doi: 10.1016/j.phymed.2023.154659
37	Chandrasekaran P, Weiskirchen R. The role of SCAP/SREBP as central regulators of lipid metabolism in hepatic steatosis[J]. Int J Mol Sci, 2024, 25 (2): 1109. doi: 10.3390/ijms25021109
38	Xu ZE, Chen Y, Huang A, et al. Inflammatory stress exacerbates lipid-mediated renal injury in ApoE/CD36/SRA triple knockout mice[J]. Am J Physiol Renal Physiol, 2011, 301 (4): F713- F722. doi: 10.1152/ajprenal.00341.2010
39	Bai X, Wang S, Shu L, et al. Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-ⅡA signaling in macrophages in mice[J]. J Ethnopharmacol, 2024, 327, 118006. doi: 10.1016/j.jep.2024.118006
40	Jiang X, Yu J, Wang X, et al. Quercetin improves lipid metabolism via SCAP-SREBP2-LDLr signaling pathway in early stage diabetic nephropathy[J]. Diabetes Metab Syndr Obes, 2019, 12, 827- 839. doi: 10.2147/DMSO.S195456
41	Zheng X, Zhong Q, Lin X, et al. Transforming growth factor-β1-induced podocyte injury is associated with increased microRNA-155 expression, enhanced inflammatory responses and MAPK pathway activation[J]. Exp Ther Med, 2021, 21 (6): 620. doi: 10.3892/etm.2021.10052
42	Kulkarni AR, Bale CB, Wakhare PS, et al. Study of the urinary TGF-β1 profile in diabetic nephropathy: a single-center experience from India[J]. Cureus, 2023, 15 (9): e45102. doi: 10.7759/cureus.45102
43	Anil Kumar P, Welsh GI, Saleem MA, et al. Molecular and cellular events mediating glomerular podocyte dysfunction and depletion in diabetes mellitus[J]. Front Endocrinol, 2014, 5, 141. doi: 10.3389/fendo.2014.00151
44	Jiang L, Cui H, Ding J. Smad3 signalling affects high glucose-induced podocyte injury via regulation of the cytoskeletal protein transgelin[J]. Nephrology, 2020, 25 (9): 659- 666. doi: 10.1111/nep.13701
45	Ying Q, Wu G. Molecular mechanisms involved in podocyte EMT and concomitant diabetic kidney diseases: an update[J]. Ren Fail, 2017, 39 (1): 474- 483. doi: 10.1080/0886022X.2017.1313164
46	Li Y, Chen S, Tan J, et al. Combination therapy with DHA and BMSCs suppressed podocyte injury and attenuated renal fibrosis by modulating the TGF-β 1/Smad pathway in MN mice[J]. Ren Fail, 2023, 45 (1): 2120821. doi: 10.1080/0886022X.2022.2120821
47	Gao F, He X, Liang S, et al. Quercetin ameliorates podocyte injury via inhibition of oxidative stress and the TGF-β1/Smad pathway in DN rats[J]. RSC Adv, 2018, 8 (62): 35413- 35421. doi: 10.1039/C8RA07935H
48	Nowacka A, Śniegocka M, Śniegocki M, et al. Sirtuins in central nervous system tumors—molecular mechanisms and therapeutic targeting[J]. Cells, 2025, 14 (14): 1113. doi: 10.3390/cells14141113
49	Tovar-Palacio C, Noriega LG, Mercado A. Potential of polyphenols to restore SIRT1 and NAD+ metabolism in renal disease[J]. Nutrients, 2022, 14 (3): 653. doi: 10.3390/nu14030653
50	Nguyen LT, Mak CH, Chen H, et al. SIRT1 attenuates kidney disorders in male offspring due to maternal high-fat diet[J]. Nutrients, 2019, 11 (1): 146. doi: 10.3390/nu11010146
51	Zhang L, Chen Z, Gong W, et al. Paeonol ameliorates diabetic renal fibrosis through promoting the activation of the Nrf2/ARE pathway via up-regulating Sirt1[J]. Front Pharmacol, 2018, 9, 512. doi: 10.3389/fphar.2018.00512
52	Jin Q, Liu T, Qiao Y, et al. Oxidative stress and inflammation in diabetic nephropathy: role of polyphenols[J]. Front Immunol, 2023, 14, 1185317. doi: 10.3389/fimmu.2023.1185317
53	Ali M, Hassan M, Ansari SA, et al. Quercetin and kaempferol as multi-targeting antidiabetic agents against mouse model of chemically induced type 2 diabetes[J]. Pharmaceuticals (Basel), 2024, 17 (6): 757. doi: 10.3390/ph17060757
54	Ge X, Wang L, Fei A, et al. Research progress on the relationship between autophagy and chronic complications of diabetes[J]. Front Physiol, 2022, 13, 956344. doi: 10.3389/fphys.2022.956344
55	Huang Y, Xia X, Xu J, et al. Mitophagy as a pivotal axis in non-alcoholic fatty liver disease: From pathogenic mechanisms to therapeutic strategies (Review)[J]. Mol Med Rep, 2025, 32 (5): 1- 15. doi: 10.3892/mmr.2025.13664
56	Selim SM, El Fayoumi HM, El-Sayed NM, et al. Alogliptin attenuates STZ-induced diabetic nephropathy in rats through the modulation of autophagy, apoptosis, and inflammation pathways: Targeting NF-κB and AMPK/mTOR pathway[J]. Life Sci, 2025, 361, 123307. doi: 10.1016/j.lfs.2024.123307
57	Guo J, Wu Y, Wan Z, et al. Post-translational modifications orchestrate mTOR-driven cell death in cardiovascular disease[J]. Front Cardiovasc Med, 2025, 12, 1620669. doi: 10.3389/fcvm.2025.1620669
58	Porstmann T, Santos CR, Griffiths B, et al. SREBP activity is regulated by mTORC1 and contributes to akt-dependent cell growth[J]. Cell Metab, 2008, 8 (3): 224- 236. doi: 10.1016/j.cmet.2008.07.007
59	Zhao YH. Resveratrol improves lipid metabolism in diabetic nephropathy rats[J]. Front Biosci, 2020, 25 (10): 1913- 1924. doi: 10.2741/4885
60	Sheng H, Zhang D, Zhang J, et al. Kaempferol attenuated diabetic nephropathy by reducing apoptosis and promoting autophagy through AMPK/mTOR pathways[J]. Front Med, 2022, 9, 986825. doi: 10.3389/fmed.2022.986825
61	王鑫, 吴巧敏, 黄超颖, 等. 黄芪-苍术改善糖尿病肾病糖脂代谢的网络药理学研究[J]. 天然产物研究与开发, 2019, 31 (12): 2051- 2057.
62	Zhang MY, Zheng SQ. Network pharmacology and molecular dynamics study of the effect of the Astragalus-Coptis drug pair on diabetic kidney disease[J]. World J Diabetes, 2024, 15 (7): 1562- 1588. doi: 10.4239/wjd.v15.i7.1562
63	李新宝, 庞欣欣, 彭紫凝, 等. 基于生物信息学及动物实验对芪黄固肾通络方治疗糖尿病肾病的研究[J]. 世界中医药, 2024, 19 (5): 615- 622. doi: 10.3969/j.issn.1673-7202.2024.05.002

Active ingredient	Dosage	Time	Model	Signal pathways and targets	Changes of blood lipid index	Reference
Astragaloside Ⅳ	20, 40, 80 mg/kg	12 W	HFD/STZ rats HK-2 cells	CD36/ROS/NLRP3	TG↓, TC↓, LDL-C↓, BUN↓, Scr↓, UACR↓	[16]
	40, 80 mg/kg	12 W	HFD/STZ rats podocytes	Klotho/ NF-κB/NLRP3	TG↓, TC↓, SCr↓, BUN↓, UACR↓	[20]
	25, 50, 100 mg/kg	12 W	HFD/STZ mice HK-2 cells	HIF-1α/HMOX1	TG↓, LDL-C↓, BG↓	[21]
Formononetin	25, 50 mg/kg	8 W	db/db mice	Smad3	TG↓, TC↓, FBG↓, FINS↓, IRI↓, ISI↑	[29]
Formononetin	25, 50 mg/kg	8 W	db/db mice GMCs	Sirt1/Nrf2/ARE	TG↓, TC↓, SCr↓, BUN↓, ACR↓	[35]
Quercetin	50, 100 mg/kg	10 W	db/db mice	SCAP-SREBP2-LDLr/ HMGCR	TG↓, TC↓, LDL-C↓, Crea↓, Urea↓, HDL-C↑	[40]
	50, 100 mg/kg	12 W	db/db mice	TGF-β1/Smad	TG↓, BUN↓, Ccr↓	[47]
	50 mg/kg	5 W	HFD/STZ rats	Sirt1/Nrf2/HO-1	TG↓, LDL-C↓, HDL-C↑	[52]
Kaempferol	50, 100 mg/kg	12 W	db/db mice	AMPK/mTOR	TC↓, LDL-C↓, SCr↓, UACR↓, FBG↓	[60]

Active ingredient	Dosage	Time	Model	Signal pathways and targets	Changes of blood lipid index	Reference
Astragaloside Ⅳ	20, 40, 80 mg/kg	12 W	HFD/STZ rats HK-2 cells	CD36/ROS/NLRP3	TG↓, TC↓, LDL-C↓, BUN↓, Scr↓, UACR↓	[16]
	40, 80 mg/kg	12 W	HFD/STZ rats podocytes	Klotho/ NF-κB/NLRP3	TG↓, TC↓, SCr↓, BUN↓, UACR↓	[20]
	25, 50, 100 mg/kg	12 W	HFD/STZ mice HK-2 cells	HIF-1α/HMOX1	TG↓, LDL-C↓, BG↓	[21]
Formononetin	25, 50 mg/kg	8 W	db/db mice	Smad3	TG↓, TC↓, FBG↓, FINS↓, IRI↓, ISI↑	[29]
Formononetin	25, 50 mg/kg	8 W	db/db mice GMCs	Sirt1/Nrf2/ARE	TG↓, TC↓, SCr↓, BUN↓, ACR↓	[35]
Quercetin	50, 100 mg/kg	10 W	db/db mice	SCAP-SREBP2-LDLr/ HMGCR	TG↓, TC↓, LDL-C↓, Crea↓, Urea↓, HDL-C↑	[40]
	50, 100 mg/kg	12 W	db/db mice	TGF-β1/Smad	TG↓, BUN↓, Ccr↓	[47]
	50 mg/kg	5 W	HFD/STZ rats	Sirt1/Nrf2/HO-1	TG↓, LDL-C↓, HDL-C↑	[52]
Kaempferol	50, 100 mg/kg	12 W	db/db mice	AMPK/mTOR	TC↓, LDL-C↓, SCr↓, UACR↓, FBG↓	[60]

[1]	Xuewu LIU, Dejian JIANG, Yanhua DU. Progress in pathogenesis and drug development of diabetic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2026, 31(6): 735-751.
[2]	WEI Xiaocheng, LI Xinrong, HE Jungang, LI Xu, QIANG Zhengze, WANG Yan, WANG Mingwei, LI Chengyi. Research progress on antitumor effects of Hedysari radix and active components [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(8): 1112-1121.
[3]	REN Menghan, YAO Jianli, YANG Lixia, SHU Chang. Effect and mechanism of extracts from oxytropis falcata on improving oxidative damage of podocytes induced by high glucose via regulating PI3K/AKT/Nrf2 pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(10): 1361-1373.
[4]	LI Wen, JIANG Hugang, WANG Xinqiang, LI Yingdong, LIU Kai, ZHAO Xinke. Exploring the mechanism of Radix Angelica sinensis and Astragalus mongholicus extract therapy for radiationinduced myocardial fibrosis based on network pharmacology and experimental validation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 601-611.
[5]	ZHU Wenhui, CHEN Yao, ZHANG Yonggang, LIU Peng. Progress in the treatment of lipid deposition in diabetic nephropathy with traditional Chinese medicine targeting nuclear receptors [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 680-689.
[6]	XU Yiqi, WU Qian, LIU Shu, LIU Fan, XING Chunyan, LI Qin, HE Junjun, HE Chunling, ZHAO Yongli, GAO Jialin. Clinical efficacy and anti-inflammation/anti-fibrosis effect of tripterygium glycosides in the treatment of diabetic nephropathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1034-1042.
[7]	LI Shan, LIU Yixin, REN Feifei, LI Xiangchen, ZHANG Zhiqing. Research progress of natural plant active ingredients in reversing tumor multidrug resistance by down-regulating P-gp [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 331-340.
[8]	CHEN Shengfu, LI Xiaolin, WANG Weigang, DU Weize, LI Maoxing. Research progress on antipyretic effect of Chinese medicine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 334-344.
[9]	LI Hongli, WEN Dandan, ZHOU Meiliang, WANG Haihua, PENG Xixu, GAO Lichen. Advances in extraction and mechanism of antitumor active components from Fagopyrum dibotrys [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 833-840.
[10]	ZHENG Chun-song, CHEN Li-wu, DU Jian, YE Hong-zhi. Study on anti-tumor mechanism of Chinese medicine Fuzhengyiliufufang by molecular docking method [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(8): 892-895.
[11]	CHEN Bing-luan, SHENG Liang-hong, LI Ping, ZOU Han-fa, ZHANG Lu-yong. Analysis of biologically active compounds in Erzhi Pills and its compositions by immobilized liposome chromatagraphy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(7): 776-779.
[12]	XING Ji-Ping, BAO Ju-Tai, LI Zhi-Tian, SUN Guo, ZHANG Rui-Hong, WANG Shuang-Min. Clinical evaluation of antitoxin cachet for coxsackie B myocarditis in treatment ofPatients with viral myocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2003, 8(6): 701-703.